Coronary vasomotion, which controls myocardial perfusion, is closely regulated by myocardial metabolic demand and has been assessed by changes of coronary vascular resistance. Only two decades ago evidence of neural and hormonal control overriding the metabolic control of coronary arterioles, which represent the "resistance vessels" was reported (fig 1) . Numerous groups reported persistence of a coronary vasodilator reserve or progressive vasoconstriction despite ischaemia.1-11 Studies showed that a adrenergic receptor mediated coronary constriction may restrict metabolic dilatation to avoid wasting blood flow to the heart muscle. ' Springer Verlag, 1988:454-64.) culature for various mediators, and the physiological significance of such mediators remains obscure.
Coronary vasomotion, which controls myocardial perfusion, is closely regulated by myocardial metabolic demand and has been assessed by changes of coronary vascular resistance. Only two decades ago evidence of neural and hormonal control overriding the metabolic control of coronary arterioles, which represent the "resistance vessels" was reported (fig 1) . Numerous groups reported persistence of a coronary vasodilator reserve or progressive vasoconstriction despite ischaemia.1-11 Studies showed that a adrenergic receptor mediated coronary constriction may restrict metabolic dilatation to avoid wasting blood flow to the heart muscle.'2 Infusion of a receptor stimulating or blocking drugs, and activation of the sympathetic nervous system during ,B blockade, defined the potential of such influences on coronary blood flow.'314 a Receptor coronary constriction may be one component of the constrictor tone during ischaemia.'4-18 In the meantime, numerous mediators have been identified which may constrict or dilate coronary vessels. Effect of lowering perfusion pressure of a cannulated coronary artery (from right to left) in analogy to progressive coronary stenosis on coronary conductance as determined distal to "coronary stenosis". Solid line represents control situation with an initial autoregulatory increase in coronary conductance (coronary vasodilatation). Further lowering of coronary perfusion pressure to induce myocardial ischaemia (left of broken vertical line), as indicated by lactate production and depression of myocardialfunction, results in a decrease rather than a further increase in coronary conductance, indicating exhaustion of coronary autoregulation. Intracoronary infusion of adenosine increases coronary conductance, suggesting a vasodilator reserve or a constrictive tone despite myocardial ischaemia. The cyclo-oxygenase inhibitor indomethacin reduces coronary conductance, suggesting a vasodilator tone of cyclo-oxygenase products of arachidonic acid in this model of myocardial ischaemia. (Ertl G. Effect of angiotensin-converting enzyme inhibitors on myocardial perfusion. In: Schultheiss HP, ed. New concepts of viral heart disease. Berlin: Springer Verlag, 1988:454-64.) culature for various mediators, and the physiological significance of such mediators remains obscure.
Vasomotion of large conductance vessels does not normally contribute to regulation of coronary blood flow. However, in the presence of atherosclerotic lesions, coronary thrombosis, and spasm, large vessels limit myocardial perfusion and induce ischaemia, angina pectoris, and infarction. Abnormal vasomotion of large coronary vessels has been appreciated in the last decades, when coronary angiography became available during acute coronary syndromes. Atherosclerotic vessels seem to respond with vasoconstriction in situations where vasodilatation should be required. The endothelium and mediators released by the endothelium play a critical role in mediating vasomotion in normal and diseased large and small coronary vessels. However, multiple potential mediators confuse our understanding of coronary vasomotion.
Previously, agonists and antagonists of various mediator systems have been used to identify a potential role for coronary vasomotion. Effects of agonists are dose dependent, and it remains unclear from most studies which concentrations of agonists may occur under physiological or pathophysiological conditions. The use of antagonists might increase our understanding, but the specificity of available inhibitors is limited. In addition, the effect of mediators is balanced by other mediators, and blockade of one may activate others. For the coronary circulation, the situation is even more complicated since coronary blood flow is under the influence of aortic pressure, compressive forces of the ventricle, and myocardial metabolic demand. Thus interventions in the coronary circulation with any agonist or antagonist result in complex changes which are difficult to analyse. Response to mediators may be different in various sections of coronary circulation,'9 and diseases which alter vasomotion may affect large and small vessels differently. Finally, acute effects of an agonist or antagonist may be different from chronic effects. Changes of coronary vascular muscle tone are responsible for acute coronary vasomotion, but coronary vasomotion may well be influenced by chronic morphological changes of the coronary vessel wall and perivascular tissue.
Importance of the renin-angiotensin system for instantaneous regulation of coronary vascular tone Two components of the renin-angiotensin system are now generally recognised: a systemic circulating, and a local renin-angiotensin system. The systemic system controls acute changes of vascular tone and aldosterone release from the adrenals. The local system may control chronic adaptation of the vasculature and perivascular tissue, the growth of smooth muscle cells, cardiac myocytes and fibroblasts, and accumulation of connective tissue. The active moiety of the system controlling coronary vasomotion is angiotensin II. Angiotensin II is liberated by the carboxypeptidase angiotensin converting enzyme (ACE) from the peptide angiotensin I. Angiotensin I is cleaved from the protein angiotensinogen by the proteinase renin. Infusion of angiotensin I to isolated heart preparations results in coronary vasoconstriction, indicated by a dose dependent reduction of coronary blood flow.20-22 Angiotensin II exerts a direct coronary vasoconstrictor effect in humans.2324 This proves the existence of ACE and angiotensin II receptors in the coronary vascular system. The relation of blood flow reduction by angiotensin I to blood flow reduction by angiotensin II may be used to calculate the conversion of angiotensin I to angiotensin II, which has been found to be 10-100% in different models under various conditions.20-22 Immunohistology and in vitro hybridisation studies suggest that in the heart ACE is present in the endocardium, epicardial coronary vessels, and in the myocardium.2526 Conversion of angiotensin I to angiotensin II is regulated under pathophysiological conditions.
Effects of inhibitors of the reninangiotensin system on coronary vessels ACE inhibitors and angiotensin II receptor antagonists have no effect on coronary blood flow in preparations without activation of the renin-angiotensin system27 28 and in patients without heart disease. However, in the latter, the ACE inhibitor teprotide dramatically increased coronary blood flow in three patients with high plasma renin, suggesting a renin dependent coronary effect of teprotide. This effect was also reflected by a good correlation between plasma renin activity and changes of coronary flow after teprotide.29 These (AT,) receptor antagonist (losartan) induced greater coronary vasodilatation than an ACE inhibitor (enalaprilat), and substantially augmented coronary blood flow.3' In rats, sodium depleted dogs, patients pretreated with the diuretic frusemide, and patients with renovascular hypertension which resulted in activation of the renin-angiotensin system, coronary blood flow increased following treatment with converting enzyme inhibitor or angiotensin II receptor antagonist proportionally to pretreatment plasma renin activity.2728 3233
Pathological conditions HYPOXIA Perfusion of the isolated rat heart with hypoxic buffer resulted in an increase in coronary flow and reduced the effect of both angiotensin I and angiotensin II on coronary blood flow.22 However, during hypoxia, the effect of angiotensin I was almost identical to that of angiotensin II, and the conversion calculated by ED50 was approximately 100% (table) . Reoxygenation restored the effects of angiotensin I and angiotensin II to control levels, suggesting a reversible rearrangement of the angiotensin II receptor or its second messengers, release of an antagonist to angiotensin II, or upregulation of converting enzyme activity, respectively. In other studies, captopril, enalapril, and ramiprilat increased coronary flow during hypoxia in isolated rat hearts and prevented a fall of coronary flow, which occurred after 15 minutes of hypoxia.34 The ACE inhibitor teprotide increased myocardial blood flow in intact hypoxic dogs,28 suggesting potential control of coronary blood flow by angiotensin II under these conditions.
ISCHAEMIA
In the isolated rat heart, the effect of angiotensin II on coronary vessels was unaffected by ischaemia, while the effect of angiotensin I was enhanced. These data indicate that conversion of angiotensin I was increased to more than 80% in the ischaemic isolated heart from approximately 10% in the control.22 During one hour of perfusion, ACE inhibitors increased coronary flow.3" The angiotensin II receptor blocker saralasin had no effect on coronary blood flow in the ischaemic isolated heart, arguing against a potential role of locally released angiotensin II on coronary vascular tone.22 When angiotensin I was infused into isolated hearts to reduce coronary flow, this flow reduction could be prevented by captopril.36
In dogs with coronary blood flow controlled by a coronary cannula, the vasoconstrictor effect of angiotensin I and angiotensin II was attenuated by a reduction of coronary perfusion pressure, which induced ischaemia.37 However, in other models of myocardial ischaemia, an activation of the renin-angiotensin system has been shown.37'2 In intact models, increased availability of angiotensin II at the receptor is likely and may be responsible for an attenuated response to exogenous angiotensin II by the coronary vascular sys-The renin-angiotensin system and coronary vasomotionl tem. An effect of inhibitors of the reninangiotensin system on coronary blood flow can also be shown in these models.
Several studies employing the use of ACE inhibitors have suggested a role for angiotensin II in blood flow regulation during ischaemia. In anaesthetised dogs, plasma renin activity and angiotensin II concentrations were increased above control as early as 30 seconds after coronary occlusion.57 When coronary occlusion was released, characteristic reactive hyperaemia occurred with flow repayment and lactate production.57 When the animals were pretreated with the ACE inhibitor captopril or the angiotensin II receptor antagonist saralasin, coronary flow repayment and lactate production were significantly reduced, supporting a potential role for angiotensin II in blood flow regulation during ischaemia. When coronary occlusion was maintained for 15 to 30 minutes, the increase in plasma renin activity persisted.5'34' Both the ACE inhibitor captopril and the angiotensin II receptor antagonist saralasin significantly increased myocardial blood flow to regions surrounding the ischaemic zone, but not in the centre of ischaemia, and had no effect in sham operated animals without coronary occlusion. In the same model, six hours after coronary occlusion plasma renin activity was still increased, and both the ACE inhibitor and the angiotensin II antagonist increased coronary blood flow over control and reduced systemic vascular resistance and left atrial pressure.'2 In animals in which nephrectomy was performed three hours before coronary occlusion, captopril had no effect on perfusion of viable myocardium and reduced perfusion of the centre ischaemic zone."39 Unloading of the heart, while improving coronary blood flow, was probably responsible for a reduction of myocardial infarct size in this model. In an isolated heart model of coronary occlusion (for 0 1 (Ertl G, 19873 ). *P < 0-01 v sinus rhythln (n = 6). 20 minutes) and reperfusion, pretreatment with the ACE inhibitor ramiprilat or the angiotensin II receptor antagonist losartan resulted in substantial improvement of coronary blood flow in the reperfusion phase.63 45 In the most recent studies, ACE inhibitors showed some survival benefit in patients with acute myocardial infarction.4647 In patients with acute myocardial infarction, plasma renin activity and angiotensin II may increase.;" 9 The effect of inhibitors of the reninangiotensin system on coronary circulation of patients with acute infarcts is unknown.
In a model with graded reduction and control of coronary blood flow by a coronary cannula in the left anterior descending coronary artery of anaesthetised dogs, pacing to increase heart rates induced myocardial ischaemia, as indicated by a reduction of regional myocardial function and an increase in plasma renin activity.7 " Pacing in animals without critical reduction of coronary blood flow did not result in an increase in plasma renin activity.;"! Saralasin and captopril increased coronary conductance when coronary perfusion pressure was lowered to 36 mm Hg, but had no effect on normal coronary perfusion (fig 2) . When pacing was repeated during infusion of an ACE inhibitor or an angiotensin II antagonist, respectively, coronary blood flow and regional myocardial function were preserved.7
In studies where coronary perfusion pressure was not maintained constant, ACE inhibitors tended to reduce coronary flow along with a reduction of loading and arterial pressure.9"'
In patients with hypertension and angina, the ACE inhibitor captopril reduced the rate-pressure product and had no effect on coronary vascular resistance.52 Changes of coronary flow were proportional to the decrease in rate-pressure product, blood pressure, and myocardial oxygen consumption.9 Intravenous captopril tended to increase coronary blood flow and to decrease coronary vascular resistance in patients with stable angina pectoris.53 In patients with dilated cardiomyopathy, the ACE inhibitor enalaprilat increased coronary blood flow when the drug was given directly into the coronary circulation. Intravenous enalaprilat or oral captopril reduced the ratepressure product in patients with heart failure and coronary arteriovenous oxygen extraction, suggesting a relative increase in coronary blood flow.9 5 55 5) . 106 Thus the renin-angiotensin system may influence coronary vasomotion by interactions with various other mediator systems, including the sympathetic nervous system, endothelium ling dependent mechanisms, and ANF. However, we are far from understanding the quantitative ed to importance of these mechanisms or their clinivels of cal relevance at this time. swn is peptiactive Conclusion In the The physiological significance of angiotensin of the II on coronary vasomotion is unclear. Most tensin studies have shown that in individuals without ACE an activation of the renin-angiotensin system, coro-a vasoconstrictor tone of angiotensin II does been not exist on the coronary vascular system. il also When the renin-angiotensin system is actitrictor vated by dietary sodium deprivation, diuretics, lation Goldblatt mechanism, heart failure, or myomaxi-cardial ischaemia, angiotensin II gains control to the over coronary blood flow. Beneficial effects of i per-inhibitors of the renin-angiotensin system in dose-numerous models suggest a pathophysiologi- 
